Stocktoria
ImageneBio, Inc. IMA
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-03-26
ImageneBio, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -6056.4% | -1057.1% | -823.3% | -454.0% | -110.2% |
| Net margin | -5668.6% | -1044.8% | -744.2% | -440.3% | -110.1% |
| FCF margin | — | — | -875.1% | -483.7% | -200.1% |
| Return on assets | -29.6% | -229.7% | -35.5% | -39.9% | -13.8% |
| Return on equity | -34.1% | 22.8% | 54.1% | -46.8% | -16.4% |
| Current ratio | 12.49 | 0.72 | 12.58 | 7.44 | 8.70 |
| Revenue growth | -77.1% | -61.8% | -41.3% | -49.6% | 237.0% |
Source: SEC EDGAR filings · CIK 0001835579 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.